INCY News and Press, Incyte Corporation From 02/12/24

2024-02-12 11:41:12 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte buys global rights for tafasitamab from MorphoSys Agilent, Incyte to collaborate on companion diagnostics development Seeking Alpha&#...

2024-02-07 08:55:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group –  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer ...

2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...

2024-02-05 17:02:22 ET Novartis ( NYSE: NVS ) said it will acquire cancer drugmake r MorphoSys AG ( MOR ) for EUR 68/share, or an aggregate of EUR 2.7B.... Read the full article on Seeking Alpha For further details see: Novartis to buy cancer drugmaker Mo...

– Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreeme...

2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...

2024-01-30 08:45:08 ET Agilent Technologies ( NYSE: A ) and Incyte ( NASDAQ: INCY ) have collaborated to develop advanced companion diagnostics in hematology and oncology.... Read the full article on Seeking Alpha For further details see: Agilent, Incyte ...

2024-01-24 14:39:16 ET More on S&P 500 Index: Bullard Says A March Rate Cut Looks Prudent PBOC Cuts Reserve Requirements, But USD Pullback May Offer New Buying Opportunity In North America SPY: Black Swan Hiding In Plain Sight Walmart is the least shorted...

2024-01-23 17:10:35 ET Summary Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab. Petosemtamab shows solid overall response rates for head and neck cancer, whil...

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Pr...